Diabetes Mellitus Is a Strong Independent Negative Prognostic Factor in Patients with Brain Metastases Treated with Radiotherapy

Simple Summary Cerebrovascular disorders are common among cancer patients. They might influence tumor growth, treatment sensitivity and, ultimately, the prognoses of patients with brain metastases (BM). In a retrospective exploratory study, we examined if the presence of arterial hypertension, smoking, diabetes mellitus (DM), hypercholesterolemia or peripheral arterial occlusive disease has a prognostic impact in patients with BM. In uni- and multivariate analysis, the presence of DM was associated with a worse prognosis across several tumor types, while for the other cerebrovascular risk factors, significant differences in survival were not found. From molecular data, it can be hypothesized that RAGE activation plays an important role in the interaction between DM and BM. In future studies, it remains to be determined to what extent serum glucose levels and antidiabetic treatments may influence survival and if optimized antidiabetic treatment or RAGE targeted treatments are able to improve prognoses of patients with BM. Abstract Background: Brain metastases (BM) cause relevant morbidity and mortality in cancer patients. The presence of cerebrovascular diseases can alter the tumor microenvironment, cellular proliferation and treatment resistance. However, it is largely unknown if the presence of distinct cerebrovascular risk factors may alter the prognosis of patients with BM. Methods: Patients admitted for the radiotherapy of BM at a large tertiary cancer center were included. Patient and survival data, including cerebrovascular risk factors (diabetes mellitus (DM), smoking, arterial hypertension, peripheral arterial occlusive disease, hypercholesterolemia and smoking) were recorded. Results: 203 patients were included. Patients with DM (n = 39) had significantly shorter overall survival (OS) (HR 1.75 (1.20–2.56), p = 0.003, log-rank). Other vascular comorbidities were not associated with differences in OS. DM remained prognostically significant in the multivariate Cox regression including established prognostic factors (HR 1.92 (1.20–3.06), p = 0.006). Furthermore, subgroup analyses revealed a prognostic role of DM in patients with non-small cell lung cancer, both in univariate (HR 1.68 (0.97–2.93), p = 0.066) and multivariate analysis (HR 2.73 (1.33–5.63), p = 0.006), and a trend in melanoma patients. Conclusion: DM is associated with reduced survival in patients with BM. Further research is necessary to better understand the molecular mechanisms and therapeutic implications of this important interaction.

[1]  Angela Ishak,et al.  Post-Diagnostic Statin Use and its Association with Cancer Recurrence and Mortality in Breast Cancer Patients: A Systematic Review and Meta-analysis. , 2023, European heart journal. Cardiovascular pharmacotherapy.

[2]  O. Merimsky,et al.  Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer , 2023, Cancer.

[3]  J. Horbańczuk,et al.  The Journey of Cancer Cells to the Brain: Challenges and Opportunities , 2023, International journal of molecular sciences.

[4]  J. Sepúlveda,et al.  Emerging targets for cancer treatment: S100A9/RAGE , 2023, ESMO open.

[5]  D. Gladstone,et al.  Sensitizing brain metastases to stereotactic radiosurgery using hyperbaric oxygen: A proof-of-principle study. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Zhengting Chen,et al.  Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1–4 brain metastases , 2022, BMC Cancer.

[7]  R. Soffietti,et al.  Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism , 2022, Nature Medicine.

[8]  A. Sahgal,et al.  Intracranial Metastatic Disease: Present Challenges, Future Opportunities , 2022, Frontiers in Oncology.

[9]  Wei Li,et al.  Effects of Diabetes on Inflammatory Status and Prognosis in Cancer Patients , 2022, Frontiers in Nutrition.

[10]  V. Gudnason,et al.  Cerebrovascular Risk-Factors of Prevalent and Incident Brain Infarcts in the General Population: The AGES-Reykjavik Study , 2021, Stroke.

[11]  S. Yadav,et al.  Diabetes and Cancer: Risk, Challenges, Management and Outcomes , 2021, Cancers.

[12]  M. Bernaudin,et al.  Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy , 2021, Scientific Reports.

[13]  S. Lo,et al.  Risk-reduction strategies for late complications arising from brain metastases treated with radiotherapy: a narrative review. , 2021, Chinese clinical oncology.

[14]  A. Sahgal,et al.  Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study , 2020, Neuro-oncology advances.

[15]  P. Vaupel,et al.  Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study , 2020, Cancers.

[16]  Yuankai Shi,et al.  Prognostic value of pretreatment smoking status for small cell lung cancer: A meta‐analysis , 2020, Thoracic cancer.

[17]  Chan Kwon Park,et al.  Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer , 2020, BMC cancer.

[18]  Mina Wang,et al.  Diabetes and cancer: Epidemiological and biological links , 2020, World journal of diabetes.

[19]  Gang Wu,et al.  The effect of combining Endostar with radiotherapy on blood vessels, tumor-associated macrophages, and T cells in brain metastases of Lewis lung cancer , 2020, Translational lung cancer research.

[20]  R. Ruslami,et al.  Type 2 Diabetes and its Impact on the Immune System , 2020, Current diabetes reviews.

[21]  B. S. Sørensen,et al.  Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways , 2020, Frontiers in Oncology.

[22]  P. Brown,et al.  Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Townsend,et al.  Hypertension in Cancer Patients and Survivors , 2019, JACC. CardioOncology.

[24]  M. Bernaudin,et al.  VCAM-1 targeted alpha-particle therapy for early brain metastases , 2019, Neuro-oncology.

[25]  M. Bhat,et al.  Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality , 2019, Cancers.

[26]  Hengqiang Zhao,et al.  High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[27]  K. Hoffmann,et al.  Vascular white matter lesions negatively correlate with brain metastases in malignant melanoma—Results from a retrospective comparative analysis , 2019, Clinical Neurology and Neurosurgery.

[28]  Han Liu,et al.  Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer , 2018, Computational and structural biotechnology journal.

[29]  N. Simone,et al.  Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer , 2018, Breast Cancer Research and Treatment.

[30]  H. Brenner,et al.  Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis. , 2018, Cancer treatment reviews.

[31]  M. Preusser,et al.  Anti-angiogenic therapies in brain metastases , 2018, memo - Magazine of European Medical Oncology.

[32]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[33]  L. Collette,et al.  Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  A. Akabane,et al.  A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. , 2017, International journal of radiation oncology, biology, physics.

[35]  T. Tsujimoto,et al.  Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population‐based observational study , 2017, International journal of cancer.

[36]  G. Warren,et al.  The Effects of smoking status and smoking history on patients with brain metastases from lung cancer , 2017, Cancer medicine.

[37]  J. Potter,et al.  Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium , 2017, Diabetologia.

[38]  W. Willett,et al.  Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Hoffmann,et al.  White matter lesions reduce number of brain metastases in different cancers: a high-resolution MRI study , 2016, Journal of Neuro-Oncology.

[40]  Volker W Stieber,et al.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.

[41]  R. Stupp,et al.  Corticosteroids compromise survival in glioblastoma. , 2016, Brain : a journal of neurology.

[42]  W. Feng,et al.  Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes☆,☆☆ , 2016, The American journal of the medical sciences.

[43]  Wolfgang A Tome,et al.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Satoshi Suzuki,et al.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. , 2014, The Lancet. Oncology.

[45]  J. M. García-Martínez,et al.  A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose. , 2013, Journal of molecular endocrinology.

[46]  G. Armstrong,et al.  Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Brown,et al.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. , 2013, Neuro-oncology.

[48]  D. Leroith,et al.  Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. , 2013, Endocrine-related cancer.

[49]  S. Rosen,et al.  Glucose transporters in cancer metabolism , 2012, Current opinion in oncology.

[50]  S. Mathoulin-Pélissier,et al.  Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Dalton,et al.  Comorbidity and survival after early breast cancer. A review. , 2012, Critical reviews in oncology/hematology.

[53]  A. Rojas,et al.  Diabetes and cancer: Looking at the multiligand/RAGE axis. , 2011, World journal of diabetes.

[54]  M. Mehta,et al.  Presentation, patterns of care, and survival in patients with brain metastases , 2011, Cancer.

[55]  D. Shibata,et al.  Vascular risk factors and longitudinal changes on brain MRI , 2011, Neurology.

[56]  K. Zänker,et al.  Diabetogenic glucose and insulin concentrations modulate transcriptom and protein levels involved in tumour cell migration, adhesion and proliferation , 2010, British Journal of Cancer.

[57]  L. Pantoni Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges , 2010, The Lancet Neurology.

[58]  B. Felding-Habermann,et al.  Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. , 2010, The American journal of pathology.

[59]  A. Rojas,et al.  Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. , 2010, Carcinogenesis.

[60]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[61]  P. Mazzone,et al.  Small Vessel Ischemic Disease of the Brain and Brain Metastases in Lung Cancer Patients , 2009, PloS one.

[62]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[63]  A. Wolff,et al.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.

[64]  B. Zinman,et al.  The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.

[65]  M. Extermann,et al.  Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Soffietti,et al.  Management of brain metastases , 2002, Journal of Neurology.

[67]  M. Bousamra,et al.  Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[68]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[69]  P. Wen,et al.  Management of brain metastases. , 1999, Oncology.

[70]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[71]  R. Strowd,et al.  Impact of diabetes mellitus on outcomes in patients with brain metastasis treated with stereotactic radiosurgery. , 2018, Journal of radiosurgery and SBRT.

[72]  F. Trimarchi,et al.  Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. , 2018, Metabolism: clinical and experimental.

[73]  D. Knopman,et al.  Vascular risk factors and longitudinal changes on brain MRI The ARIC study , 2011 .

[74]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.